Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 1

The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?

Pages
204–213
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Programmed death ligand-1 (PD-L1) is a predictive marker for immunotherapeutic agents.
📊
Key Findings & Data:However, heterogeneous staining of PD-L1 can cause false-negative results.
💡
Conclusion & Impact:Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Programmed death ligand-1 (PD-L1) is a predictive marker for immunotherapeutic agents. However, heterogeneous staining of PD-L1 can cause false-negative results. The aim of this study is to evaluate the importance of histological patterns on PD-L1 staining heterogeneity in lung adenocarcinomas (LAC). Materials and methods: PD-L1 immunohistochemistry (IHC) stain was performed to two different tissue cores of 128 LAC cases, and cut-off values are given for grouping the cases according to the percentage of staining (1%-10%, 11%-49%, 50%-100%). Staining rates between cores were compared and analyzed by their histological patterns. Also, the relation of the PD-L1 expression with the clinicopathological characteristics of the cases was analyzed. Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off. PD-L1 expression was significantly related to the high grade micropapillary and solid patterns of adenocarcinomas (p:0.01). Staining cut-offs were mostly similar between cores (43/50, 86%) (k:0.843). However, 14% of them were positive only in one core (7 of 50). This false negativity was mostly related to the histological patterns. Conclusion: Our data reveal the heterogeneous staining of PD-L1 expression, also micropapillary and solid patterns show higher rates of PDL expression. Therewithal, these findings also highlight the importance of taking into consideration of histological patterns, when choosing a paraffin block for the PDL1.Key words: PD-L1, lung cancer, immunotherapy, lung adenocarcinoma

🔖

Cite This Article

BULUTAY, P., FIRAT, P., ZEREN, H., ERUS, S., TANJU, S., DİLEGE, Ş. (2022). The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 1, 204–213. https://ajindex.com/articles/609535

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218. doi: org/10.1038/nature12213 2. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N et al. Non-small-cell lung cancer. Nature Reviews Disease Primers 2015; 1 (15009). doi: org/10.1038/nrdp.2015.9 3. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR et al. Cancer treatment and survivorship statistics, 2019. A Cancer Journal for Clinicians 2019; 69: 363-385. doi: org/10.3322/caac.21565 4. Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget 2017; 8 (30): 50209-50220. doi: 10.18632/oncotarget.16854 5. Chang L, Hui Y, Qianqian L, Haiquan C, Yuan L et al. Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center. Frontiers Oncology 2019; 9: 1116. doi: 10.3389/fonc.2019.01116 6. Gubens MA, Davies M. NCCN Guidelines Updates: New ımmunotherapy strategies for ımproving outcomes in non-small cell lung cancer. The Journal of the National Comprehensive Cancer Network 2019; 17: 574-578. doi: org/10.6004/jnccn.2019.5005 7. Chen F, Zhuang X, Lin L, Yu P, Wang Y et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Medical 2015; 13: 45. doi: 10.1186/ s12916-015-0278-7 8. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine 2015; 21 (1): 24-33. doi: org/10.1016/j.molmed.2014.10.009 9. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 29; 313(5795):1960-1964. doi: 10.1126/science.1129139 10. Okazaki T, Honjo T. PD-1 and PD-1 ligands: From discovery to clinical application. International Immunology 2007; 19: 813- 824. doi: org/10.1093/intimm/dxm057 11. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunology Immunotherapy 2007; 56 (5): 739-745. doi: org/10.1007/ s00262-006-0272-1 12. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. European Journ